Table 3.

Effect of intensive home treatment and care as usual on self-efficacy dimensions during 26 weeks

Linear mixed modelling analyses
Self-efficacy dimensions	N	Main effects	B	95% CI		SE	DF	t	p
				Lower	Upper
Optimism	116	Intercept	2.09	1.58	2.61	0.26	127.12	8.02	< 0.001
		Baseline Optimism	0.54	0.44	0.65	0.05	112.82	10.08	< 0.001
		Treatment	− 0.08	− 0.41	0.25	0.17	178.88	− 0.50	0.62
		Time	− 0.05	− 0.33	0.24	0.14	106.09	− 0.32	0.75
		Time*Treatment	− 0.08	− 0.44	0.27	0.18	106.79	− 0.46	0.65
Advocacy	116	Intercept	3.05	2.53	3.57	0.26	124.13	11.57	< 0.001
		Baseline Advocacy	0.38	0.27	0.48	0.05	105.68	7.03	< 0.001
		Treatment	− 0.12	− 0.44	0.20	0.16	197.72	− 0.74	0.46
		Time	0.04	− 0.28	0.36	0.16	102.04	0.23	0.82
		Time*Treatment	− 0.01	− 0.41	0.39	0.20	103.00	− 0.07	0.95
Coping	115	Intercept	2.15	1.65	2.64	0.25	128.64	8.60	< 0.001
		Baseline Coping	0.50	0.39	0.61	0.06	115.19	8.94	< 0.001
		Treatment	− 0.02	− 0.35	0.32	0.17	170.10	− 0.09	0.93
		Time	0.05	− 0.23	0.33	0.14	104.35	0.33	0.74
		Time*Treatment	− 0.15	− 0.50	0.20	0.18	104.65	− 0.85	0.40
Self-efficacy	115	Intercept	2.15	1.68	2.61	0.23	123.54	9.15	< 0.001
		Baseline Self-efficacy	0.53	0.43	0.63	0.05	112.67	10.30	< 0.001
		Treatment	− 0.08	− 0.36	0.20	0.14	172.85	− 0.55	0.59
		Time	− 0.01	− 0.24	0.22	0.12	103.95	− 0.06	0.95
		Time*Treatment	− 0.08	− 0.37	0.21	0.15	104.66	− 0.57	0.57

The outcome based on a per-protocol analysis, based on estimated marginal means

Self-efficacy the total of all self-efficacy dimensions, N number of participants included in the analysis, B estimated regression coefficient, CI confidence interval, SE standardised error, DF degrees of freedom, t T-test value